Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc.

September 10, 2009 09:10 ET

Critical Outcome Technologies Inc. Launches Upgrade of Its Comprehensive and Innovative Drug Discovery, Profiling and Optimization Technology

LONDON, ONTARIO--(Marketwire - Sept. 10, 2009) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that the Company has implemented the next generation upgrade of its proprietary platform technology CHEMSAS® version 10A for the rapid discovery, profiling, optimization and selection of targeted small libraries of potential lead molecules. The important aspects of the upgrade include:

1. The CHEMSAS molecular profiling process has been automated, resulting in a significant decrease in the turnaround time to generate novel small molecule libraries. Prior to this modification, COTI was able to identify lead candidates in about twelve weeks. With this advancement, COTI is now able to handle this task in a matter of days to two weeks.

2. COTI's proprietary database, CHEMBase, has been upgraded and now contains more than 500,000 unique molecular data patterns with multiple biological activities.

3. The proprietary CHEMSAS descriptor set has been expanded and new proprietary data transforms have been implemented to better capture complex 3D molecular structure information and distinguish between close isomers.

4. Expanded data sets, improved descriptors, new data transformations and new machine learning algorithms have been used to develop and validate a comprehensive system of new models for predicting important molecular properties.

5. Taken together, the above developments enable COTI to complete multiple internal and customer initiated projects in parallel and much faster than previous versions of CHEMSAS.

"In practical terms, we are seeing a four-fold increase in the number of projects we can work on at any given time," said Dr. Wayne Danter, President and Chief Scientific Officer of COTI. "The automation and upgrade of our core technology, CHEMSAS, resulting from the efforts of three scientists and more than a year of work, represents another important milestone in the continued growth and development of our company. This productivity increase will directly and positively impact our revenue generating capabilities as our technology becomes more widely accepted."

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development; small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, adult acute leukemia, colorectal cancer and Alzheimer's disease.

For further information, please visit the website at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Critical Outcome Technologies Inc.
    Michael Barr
    Director of Business Development and Marketing